Exact Sciences
The company recently acquired PFS Genomics, which has developed a test to determine the necessity of radiotherapy for breast cancer patients.
Exact Sciences Reports 16 Percent Q1 Revenues Rise, Acquires PFS Genomics for $30.6M
The company said screening revenues, from Cologuard tests and Biomatrica products, rose 10 percent year over year during the quarter.
The 20-year study showed the test provided an accurate assessment of the risk of long-term metastases and mortality for patients with localized prostate cancer.Â
In Brief This Week: Exact Sciences, Siemens Healthineers, Seegene, Agilent Technologies, and More
News items for the in vitro diagnostics industry for the week of April 12, 2021.
COVID-19 Pandemic Changing Digital Innovations, Care Models for Lab Industry, Panelists Say at ACLA
Premium
At ACLA's annual meeting, a panel discussed how machine learning, artificial intelligence, telehealth, and at-home testing have gained traction throughout the laboratory industry.
Jan 11, 2021